Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Recruiting

Phase 1

Phase 2

Peposertib & AvelumabTesting the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Sponsor:

National Cancer Institute (NCI)

Code:

NCT04068194

Conditions

Locally Advanced Malignant Solid Neoplasm

Locally Advanced Unresectable Cholangiocarcinoma

Locally Advanced Unresectable Gallbladder Carcinoma

Locally Advanced Unresectable Malignant Solid Neoplasm

Metastatic Cholangiocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Avelumab

Biopsy Procedure

Biospecimen Collection

Computed Tomography

Hypofractionated Radiation Therapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-29. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-04-09.